July 23, 2017 1:25 PM ET

Pharmaceuticals

Company Overview of Claris Lifesciences Limited

Company Overview

Claris Lifesciences Limited, together with its subsidiaries, manufactures and sells drugs and pharmaceuticals worldwide. It manufactures and markets products for anesthesia and analgesics, blood products, anti-infectives, plasma volume expanders, critical care, and nephrology areas, as well as for infusion therapy and nutrition applications. The company also provides dialysis and transplant range across systems, solutions, medicines, disposables, and equipment. In addition, it offers injectables for various therapeutic groups, including anti-emetics, CNS, cardiology, anti-malaria, haematinics, etc. The company offers its products through various delivery systems, such as glass and plastic bo...

Near Parimal Railway Crossing

Ellisbridge

Ahmedabad,  380006

India

Founded in 1994

1,324 Employees

Phone:

91 79 2656 3331

Fax:

91 79 2640 8053

Key Executives for Claris Lifesciences Limited

Vice Chairman and Managing Director
Age: 37
Total Annual Compensation: 6.0M
Chief Financial Officer and Whole Time Director
Age: 43
Total Annual Compensation: 9.7M
Senior Vice President, Compliance Officer and Company Secretary
Total Annual Compensation: 8.5M
Compensation as of Fiscal Year 2016.

Claris Lifesciences Limited Key Developments

Claris Lifesciences Limited Declares Third Quarter Cash Dividend, Payable on August 14, 2017

Claris Lifesciences Limited declared third quarter cash dividend of $0.55 per share, payable on August 14, 2017 to shareholders of record on July 17, 2017.

Claris Lifesciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2017

The Board of Directors of Claris Lifesciences Limited has recommended a final dividend of INR 2 per equity share of INR 10 each for the financial year ended March 31, 2017, subject to the approval of shareholders at the ensuing annual general meeting.

Claris Lifesciences Limited Announces Unaudited Standalone and Consolidated Financial Results for the Fourth Quarter and Audited Consolidated and Standalone Financial Results for Year Ended March 31, 2017

Claris Lifesciences Limited announced unaudited standalone and consolidated financial results for the fourth quarter and audited consolidated and standalone financial results for year ended March 31, 2017. For the quarter, on standalone basis, the company reported revenue from operation of INR 30,925,000 against INR 89,299,000 for the same period a year ago. Total income was INR 8,563,000 against INR 195,379,000 for the same period a year ago. Loss before taxation from continuing operations was INR 129,826,000 against INR 125,271,000 for the same period a year ago. Loss for the period from continuing operations was INR 92,016,000 against INR 67,831,000 for the same period a year ago. Loss for the period was INR 57,414,000 against Profit for the period of INR 4,430,000 for the same period a year ago. Diluted loss per share from continuing operations was INR 1.69 per share against INR 1.24 per share for the same period a year ago. Diluted loss per share from continuing & discontinued operations was INR 1.05 per share against Diluted earnings per share from continuing & discontinued operations INR 0.08 per share for the same period a year ago. For the year, on standalone basis, the company reported revenue from operation of INR 211,162,000 against INR 1,220,538,000 for the same period a year ago. Total income was INR 691,420,000 against INR 1,645,722,000 for the same period a year ago. Loss before taxation from continuing operations was INR 180,664,000 against INR 433,268,000 for the same period a year ago. Loss for the period from continuing operations was INR 50,910,000 against INR 410,282,000 for the same period a year ago. Profit for the period was INR 115,556,000 against loss for the period of INR 202,625,000 for the same period a year ago. Diluted loss per share from continuing operations was INR 0.93 per share against INR 7.52 per share for the same period a year ago. Diluted earnings per share from continuing & discontinued operations were INR 2.12 per share against Diluted loss per share from continuing & discontinued operations INR 3.71 per share for the same period a year ago. For the quarter, on consolidated basis, the company reported revenue from operation of INR 44,109,000 against INR 182,374,000 for the same period a year ago. Total income was INR 137,265,000 against INR 271,150,000 for the same period a year ago. Loss before taxation from continuing operations was INR 106,155,000 against INR 152,053,000 for the same period a year ago. Loss for the period from continuing operations was INR 56,489,000 against INR 90,402,000 for the same period a year ago. Profit for the period was INR 369,643,000 against loss for the period of INR 6,177,000 for the same period a year ago. Loss for the period from continuing operations attributable to owners of the company was INR 56,489,000 against INR 90,402,000 for the same period a year ago. Diluted loss per share from continuing operations was INR 1.04 per share against INR 1.66 per share for the same period a year ago. Diluted earnings per share from continuing & discontinued operations were INR 6.77 per share against Diluted loss per share from continuing & discontinued operations INR 0.12 per share for the same period a year ago. For the year, on consolidated basis, the company reported revenue from operation of INR 255,287,000 against INR 1,331,625,000 for the same period a year ago. Total income was INR 629,875,000 against INR 1,790,100,000 for the same period a year ago. Loss before taxation from continuing operations was INR 596,974,000 against INR 1,335,680,000 for the same period a year ago. Loss for the period from continuing operations was INR 401,426,000 against INR 1,106,530,000 for the same period a year ago. Profit for the period was INR 1,099,250,000 against loss for the period of INR 394,350,000 for the same period a year ago. Loss for the period from continuing operations attributable to owners of the company was INR 401,426,000 against INR 1,106,530,000 for the same period a year ago. Diluted loss per share from continuing operations was INR 7.36 per share against INR 20.28 per share for the same period a year ago. Diluted earnings per share from continuing & discontinued operations were INR 20.14 per share against Diluted loss per share from continuing & discontinued operations INR 7.23 per share for the same period a year ago.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 8, 2017
Otsuka Pharmaceutical India Private Limited
Merger/Acquisition
December 15, 2016
Claris Injectables Limited
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Claris Lifesciences Limited, please visit www.clarislifesciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.